Navy@3x
Navy@3x

Convergent development of unique treatment systems for retinal disorders

Oxular’s technologies were developed together to find solutions that would solve significant remaining unmet challenges in retinal care. Together, these systems will transform the treatment of retinal disorders.

Convergent development of unique treatment systems for retinal disorders

Oxular’s technologies were developed together to find solutions that would solve significant remaining unmet challenges in retinal care. Together, these systems will transform the treatment of retinal disorders.

Oxular’s product pipeline is built on our innovative technologies:

Targeted, routine suprachoroidal delivery

Oxulumis®

Long-lasting
treatments

Oxuspheres™

Our technologies are designed to provide retinal specialists with innovative treatment approaches, to solve serious and persistent issues facing retinal patients.

Oxulumis®

Oxulumis is a minimally invasive, semi-automated administration device for routine delivery of therapeutics via an illuminated microcatheter to the posterior suprachoroidal space of the eye.

Key features of Oxulumis®

Tissue interface accommodates variations in scleral thickness

Semi-automated deployment of microcatheter reliably accesses the suprachoroidal space

Transscleral illumination of microcatheter confirms accurate deployment

Posterior placement of microcatheter adjacent to specific tissues involved in retinal disease

Key benefits of Oxulumis®

Minimally invasive in-office procedure with small-gauge needle insertion

Does not penetrate the intraocular space

Enables safe, routine drug administration

Drug delivery only occurs after visual confirmation of correct microcatheter placement (ensures accurate drug delivery)

Delivers drug products alongside the posterior retina and macula

Oxuspheres™

Our development products incorporate our proprietary Oxuspheres™ drug-containing, biodegradable polymer system. Oxuspheres are designed to deliver clinically therapeutic drug levels over prescribed treatment periods to the target tissues involved in retinal disorders, while maintaining low drug levels elsewhere in the eye to minimize off-target drug side effects.

Oxusphere drug products provide sustained drug treatments and have the potential to address significant unmet needs by improving patient outcomes and dramatically reducing the unsustainably high treatment burden for patients, retinal specialists, and healthcare systems.

Key features of Oxuspheres™

Safe, biodegradable, sustained-release drug product

Highly tunable to independently adjust dosing and duration

Designed to perform in targeted small spaces in the eye, such as the suprachoroidal space

Well suited for a variety of agents

Low-volume preparations avoid reflux, and significant acute elevations in intraocular pressure following administration

Key benefits of Oxuspheres™

Provides sustained treatment for up to one year following a single administration

Long-lasting treatments significantly reduce the number of annual injections and visits for patients and clinicians

Provides targeted drug distribution to the specific tissues involved in retinal diseases

Sustained therapy translates to more consistent treatment and better adherence

See our pipeline of long-lasting treatments

Oxulumis®

Oxulumis® is a minimally invasive, semi-automated administration device for routine delivery of therapeutics via an illuminated microcatheter to the posterior suprachoroidal space of the eye.

Key features of Oxulumis®

Tissue interface accommodates variations in scleral thickness

Semi-automated deployment of microcatheter reliably accesses the suprachoroidal space

Transscleral illumination of microcatheter confirms accurate deployment

Posterior placement of microcatheter adjacent to specific tissues involved in retinal disease

Key benefits of Oxulumis®

Minimally invasive in-office procedure with small-gauge needle insertion

Does not penetrate the intraocular space

Enables safe, routine drug administration

Drug delivery only occurs after visual confirmation of correct microcatheter placement (ensures accurate drug delivery)

Delivers drug products alongside the posterior retina and macula

Oxuspheres™

Our development products incorporate our proprietary Oxuspheres™ drug-containing, biodegradable polymer system. Oxuspheres™ are designed to deliver clinically therapeutic drug levels over prescribed treatment periods to the target tissues involved in retinal disorders, while maintaining low drug levels elsewhere in the eye to minimize off-target drug side effects.

Oxusphere drug products provide sustained drug treatments and have the potential to address significant unmet needs by improving patient outcomes and dramatically reducing the unsustainably high treatment burden for patients, retinal specialists, and healthcare systems.

Key features of Oxuspheres™

Safe, biodegradable, sustained-release drug product

Highly tunable to independently adjust dosing and duration

Designed to perform in targeted small spaces in the eye, such as the suprachoroidal space

Well suited for a variety of agents

Low-volume preparations avoid reflux, and significant acute elevations in intraocular pressure following administration

Key benefits of Oxuspheres™

Provides sustained treatment for up to one year following a single administration

Long-lasting treatments significantly reduce the number of annual injections and visits for patients and clinicians

Provides targeted drug distribution to the specific tissues involved in retinal diseases

Sustained therapy translates to more consistent treatment and better adherence

See our pipeline of long-lasting treatments
Scroll to Top